JOCELYN URIOSTEGUI: Open Payments
NPI 1912475633 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,829 in 80 payments from 24 companies in 2025. Trend: 2023 $1,332 · 2024 $1,804 · 2025 $1,829
Food & beverage: $1,829
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 14 | $286 |
| Lilly USA, LLC | 13 | $278 |
| SANOFI-AVENTIS U.S. LLC | 5 | $143 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $96 |
| Amphastar Pharmaceuticals, Inc. | 5 | $95 |
| CeQur Corporation | 1 | $90 |
| Amneal Pharmaceuticals LLC | 4 | $85 |
| Tandem Diabetes Care, Inc. | 4 | $85 |
| Amgen Inc. | 4 | $79 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $77 |
Products named: JARDIANCE, MOUNJARO, TZIELD, Ozempic, CeQur Simplicity, UNITHROID, t:slim X2 Insulin Pump with Control-IQ, Kerendia.
Industry payments across TX — which companies pay providers there.
